Impact Partnership Wealth LLC Takes $467,000 Position in Royalty Pharma plc (NASDAQ:RPRX)

Impact Partnership Wealth LLC purchased a new position in Royalty Pharma plc (NASDAQ:RPRX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 18,323 shares of the biopharmaceutical company’s stock, valued at approximately $467,000.

Other hedge funds also recently bought and sold shares of the company. Brooklyn Investment Group raised its position in shares of Royalty Pharma by 1,006.9% during the 4th quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 876 shares during the last quarter. Blue Trust Inc. increased its position in shares of Royalty Pharma by 362.7% during the third quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 943 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in Royalty Pharma in the 3rd quarter valued at $61,000. GAMMA Investing LLC boosted its stake in Royalty Pharma by 31.4% during the 4th quarter. GAMMA Investing LLC now owns 2,471 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 590 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Royalty Pharma by 32.1% during the second quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 655 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Price Performance

Royalty Pharma stock opened at $30.62 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.54 and a current ratio of 1.54. The company has a market capitalization of $18.04 billion, a price-to-earnings ratio of 15.87 and a beta of 0.47. The company’s 50 day simple moving average is $26.67 and its 200-day simple moving average is $27.31. Royalty Pharma plc has a 1 year low of $24.05 and a 1 year high of $31.66.

Royalty Pharma Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 21st will be given a dividend of $0.22 per share. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a dividend yield of 2.87%. The ex-dividend date is Friday, February 21st. Royalty Pharma’s dividend payout ratio (DPR) is currently 43.52%.

Wall Street Analyst Weigh In

RPRX has been the topic of several research reports. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, November 5th. Citigroup reduced their target price on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. Finally, TD Cowen upgraded shares of Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Royalty Pharma presently has a consensus rating of “Buy” and a consensus target price of $41.67.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.